Japan Supreme Court Throws Out Taiko Pharmaceutical Suit Against Izumi Yakuhin
This article was originally published in PharmAsia News
Japan's Supreme Court threw out a lawsuit July 4 brought by Taiko Pharmaceuticals against Izumi Yakuhin Kogyo. Taiko, manufacturer of gastrointestinal drug Seirogan, had asked the court to suspend sales of Izumi Seirogan from Izumi Yakuhin, manufacturer and marketer of Izumi Seirogan. The court said that Seirogan was an accepted name, and that it was easy to distinguish Taiko's product from Izumi's product. (Click here for more - Japanese language
You may also be interested in...
Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.
As draft guidance receives OMB review, FDA’s determination of no economic significance reflects its official position that the thousands of supplements, food and personal care products containing CBDs available in the US are unlawful.
AdvaMed Accell executive director Ashley Wittorf spoke in support of a proposed US House bill that would give financial help to small companies making products to address COVID-19.